The Drug Safety Research Unit (DSRU) has announced the appointment of Linda Härmark as its new director.
Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback